Healthcare - Page 1 | TalkMarkets
All Posts > Content under Healthcare
1 to 16 of 4505 Posts
1 2 3 ... 282
Week In Review: How Trump's Policies Moved Stocks - Sunday, October, 22
Article By: The Fly
Sunday, October 22, 2017 3:22 AM EDT
According to Reuters on Friday, about two dozen major companies are planning to launch The Coalition for the American Dream to urge Congress to pass bipartisan legislation to enable young, illegal immigrants to continue working in the U.S.
In this article: AET, HCA, HUM, IBM, UNH, GOOG, INTC, CNC, MAR
Read
Healthcare ETF (VHT) Hits New 52-Week High
Article By: Zacks Investment Research
Friday, October 20, 2017 8:03 PM EDT
Investors seeking momentum may have Vanguard Healthcare ETF on their radar now. The fund recently hit a new 52-week high. Shares of VHT are up approximately 29.2% from the 52-week low of $120.38/share.
In this article: JNJ, PFE, UNH, VHT
Read
Seattle Genetics Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly
Friday, October 20, 2017 8:02 AM EDT
Barclays analyst Geoff Meacham upgraded Seattle Genetics to Overweight and raised his price target for the shares to $70 from $60.
In this article: SGEN Also: REGN
Read
Healthcare ETFs Head To Head: XLV Vs. VHT
Article By: Zacks Investment Research
Thursday, October 19, 2017 6:37 PM EDT
The healthcare sector has been in the spotlight lately. President Donald Trump targeted drug companies and accused them of charging extremely high prices.
In this article: VHT, XLV Also: JNJ, UNH, PFE
Read
Is Allergan Stock Finally Going To Reward Shareholders?
Article By: Modest Money
Thursday, October 19, 2017 12:31 PM EDT
Allergan Stock has been a painful ride for investors. Starting last year when the proposed merger with Pfizer fell through, Allergan stock has fallen.
In this article: AGN
Read
Abbott (ABT) Beats Earnings And Sales In Q3, Tweaks View
Article By: Zacks Investment Research
Wednesday, October 18, 2017 10:57 AM EDT
Abbott Labs posted third quarter revenues of $6.82 billion surpassing the Zacks Consensus Estimate for revenues of $6.71 billion.
In this article: ABT
Read
Amgen May Pull Back Before The Next Surge
Article By: Bob Lang
Wednesday, October 18, 2017 9:38 AM EDT
Will Amgen provide another ideal entry point? The chart says yes.
In this article: AMGN
Read
Merck Upgraded To Buy From Neutral At Citi
Article By: The Fly
Wednesday, October 18, 2017 6:53 AM EDT
The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B.
In this article: MRK Also: LLY, RHHBY
Read
Your Stake In The $22 Billion Dollar Cannabis Industry
Article By: Modest Money
Wednesday, October 18, 2017 4:54 AM EDT
Is now the right time to invest in the Cannabis Industry? The Cannabis Stock Index is up 26.4% month-to-date.
In this article: SMG, VRX, ABBV, INSY
Read
Shire Plc (ADR) In The Spotlight As Activist Fund Sachem Pushes For More Divestment
Article By: Insider Monkey
Tuesday, October 17, 2017 5:17 PM EDT
Although M&A is a frequent occurrence in the biotech sector, major M&A is normally less common for large cap stocks.
In this article: SHPG Also: ADSK
Read
UnitedHealth (UNH) Beats On Q3 Earnings, Guides Higher
Article By: Zacks Investment Research
Tuesday, October 17, 2017 8:29 AM EDT
UnitedHealth came out with earnings per share of $2.66, beating the Zacks Consensus Estimate of $2.57. Results were aided by higher revenues from both its segments – UnitedHealthcare and Optum.
In this article: UNH
Read
Exelixis Surges After Cabometyx Granted Priority Review, Meets Endpoint In Trial
Article By: The Fly
Monday, October 16, 2017 12:50 PM EDT
Shares of Exelixis jumped in early trading after the biopharmaceutical company said it received priority review from the U.S. Food and Drug Administration for a treatment for advanced renal cell carcinoma.
In this article: EXEL Also: IPSEY, BAYRY
Read
3 Market-Beating Stocks For Your 2018 Radar (With Extreme Upside Potential)
Article By: TipRanks
Monday, October 16, 2017 8:47 AM EDT
This little-known biotech stock has only received three buy ratings from top analysts in the last three months. However, these three analysts are all confident on one thing: that Gemphire has serious upside potential.
In this article: MCRB, LITE, GEMP
Read
Week In Review: How Trump's Policies Moved Stocks - Sunday, Oct. 15
Article By: The Fly
Sunday, October 15, 2017 3:43 AM EDT
Insurers and hospital operators were under pressure on Friday after President Trump announced plans to cut off subsidy payments to insurers selling Affordable Care Act Coverage.
In this article: AET, CNC, HCA, HUM, JPM, NYT, GOOG, NWSA, FB, TWTR
Read
How To Get Involved In The Drug Trade (It’s Not What You Think)
Article By: David Zarling
Saturday, October 14, 2017 11:58 AM EDT
Eli Lilly & Co. (LLY), one of the world’s largest drug manufacturers, has seen its stock go nowhere for 2 years. This after Lilly was up over 350% from the bottom in 2009 through September 2015. Last week, it broke out of the 2-year base.
In this article: LLY
Read
Inotek Jumps After Detailing Rocket's Near-Term Clinical Catalysts
Article By: The Fly
Friday, October 13, 2017 3:12 PM EDT
Inotek Pharmaceuticals last night announced the filing with the SEC of the company's preliminary proxy statement in connection with the previously announced proposed combination with Rocket Pharmaceuticals.
In this article: ITEK
Read
1 to 16 of 4505 Posts
1 2 3 ... 282